A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to evaluate the efficacy and safety of E2609 in subjects with Early Alzheimer’s Disease

The PI of this project was: Sanjay Asthana, MD

This project was funded by: Eisai Inc.

The term of this project was: June 2017 to January 2020

The number of subjects scanned during this project was: 10